Cardiac Insight said today it raised $4.5 million in a new C-1 round of funding, looking to raise a total of $10 million in the round to support its Cardea Solo 7-day ECG sensor.
Funds from the round will support sales, distribution and marketing of the company’s wearable Cardea Solo device, designed to provide both physicians and patients with cardiac data and help diagnose a variety of arrhythmias including atrial fibrillation.
“Cardiac Insight has quickly caught the attention of the cardiology community for our game-changing products and revolutionary approach to cardiac care. Our new funding and leadership additions will continue to propel the company forward and highlight our distinct value proposition to cardiologists, healthcare institutions and patients,” CEO & co-founder Brad Harlow said in a prepared statement.
The Kirkland, Wash.-based company said that along with the funding, it formed a scientific advisory board to be led by former Heart Rhythm Society prez Dr. Robert Hauser.
Cardiac Insight also said that OncoResponse CEO Clifford Stocks will join the company’s board of directors.
“Cardiac Insight brings exclusive technology capabilities that will help save lives and empower health care providers with control over data and the patient experience, as well as increased efficiencies for the diagnosis and treatment of cardiac care. I am honored to serve with a group of healthcare executives who bring impressive track records in building new med-tech platforms,” Stocks said in a press release.
In early July, Cardiac Insight announced the launch of the Cardea Solo.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.